Federal matching funds will be unavailable for gender-affirming medications and surgeries in Medicaid beneficiaries <18 and CHIP enrollees <19, without creating an outright federal coverage ban.
Welcome back to another Managed Healthcare Executive Between the Lines series. In this opening episode, moderator Philip Mease, MD, Director of Rheumatology Research at Swedish Medical Center, ...
Patrick Gleason, Pharm.D., of Prime Therapeutics was named a 2026 PBMI Innovator for his work on cost-effective formulary ...
Commercial availability targets ~70,000 pharmacies, with anticipated payer coverage for most eligible adults with type 2 diabetes. Pricing includes a $99 list price per package and NovoCare offerings ...
A quadruple-blind, randomized design enrolled 209 children (3–17 years) to oral dexamethasone 0.5 mg/kg (max 20 mg) versus placebo on postoperative days 2, 4, and 6. Mean preanalgesic pain on days 2–8 ...
David Chen, Pharm.D., of Kaiser Permanente discusses how PBM reform could speed biosimilar adoption and lower drug costs.
The phase 3 trial will evaluate the efficacy of pemvidutide, a dual glucagon/GLP-1 receptor agonist, in metabolic dysfunction-associated steatohepatitis patients with moderate to advanced fibrosis, ...
The real challenge for health plans isn’t simply deciding how to automate prior authorization but using this regulatory moment to build a far more durable cost-management strategy. Health plans are ...
Welcome back to another Managed Healthcare Executive Between the Lines series. In this opening episode, moderator Philip Mease, MD, Director of Rheumatology Research at Swedish Medical Center, ...
A cross-sectional online survey of 296 South Korean women aged 40–64 stratified diabetes status via fasting glucose and HbA1c and quantified symptoms using the validated Midlife Women’s Symptom Index.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results